Back Login to subscribe 🔔 Set Alert

AZN AstraZeneca PLC

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre	87.92%
	AstraZeneca shares are trading lower after the company announced it entered into an exclusive global license agreement with Dizal, where it will pay $600 million upfront and up to $900 million in milestones and royalties.	96.64%
	AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties	87.63%
	Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain	75.36%
	Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo	90.42%
	Sino Biopharma Accelerates Global Growth With GSK, AstraZeneca Partnerships	90.75%
	'AstraZeneca, Daiichi Near UK Price Deal for Breast Cancer Drug' - Bloomberg	82.89%
	Helix Partners With AstraZeneca Over Access To Phenotyped GenoSphere Cohorts	86.7%
	Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance	75.09%
	AstraZeneca shares are trading higher after the company announced it entered into a strategic collaboration agreement with Abbisko Therapeutics to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer. The company and CSPC Pharmaceutical Group entered into an agreement to use the siRNA drug discovery platform to develop novel small nucleic acid drug candidates.	94.94%

1
2
›